Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique

Clinical Transplantation

Volumn 27, Issue 1, 2013, Pages 154-161

  Trifilio, Steven M ^a   Scheetz, Marc ^a   Borensztajn, Jayme ^a   Mehta, Jayesh ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Correction factor; Cyclosporine; High performance liquid chromatography; Immunoassay

Indexed keywords

CYCLOSPORIN A; MONOCLONAL ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CALCULATION; CLINICAL ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; SIMULATION; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873092135     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12037     Document Type: Article

References (20)

1. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006: 38: 169.
2. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 2010: 32: 3.
3. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991: 13: 465.
4. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993: 57: 291.
5. Holt DW, Johnston A. Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit 1995: 17: 625.
6. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998: 92: 2303.
7. Nash RA, Antin JA, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation. Blood 2000: 96: 2062.
8. Hiraoka A, Ohashi Y, Okamoto S et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001: 28: 181.
9. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 1999: 45: 371.
10. Chan GL, Weinstein SS, LeFor WW, Spoto E, Kahana L, Shires DL. Relative performance of specific and nonspecific fluorescence polarization immunoassay for cyclosporine in transplant patients. Ther Drug Monit 1992: 14: 42.
11. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990: 36: 1969.
12. Bowers LD. Cyclosporine analysis by high-performance liquid chromatography: precision, accuracy, and minimum detectable quantity. Transplant Proc 1990: 22: 1150.
13. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988: 319: 65.
14. Schumann G, Petersen D, Hoyer PF, Wonigeit K. Monitoring cyclosporin A (ciclosporin, INN) concentrations in whole blood: evaluation of the Emit assay in comparison with HPLC and RIA. Eur J Clin Chem Clin Biochem 1993: 31: 381.
15. Winkler M, Schumann G, Petersen D, Oellerich M, Wonigeit K. Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. Clin Chem 1992: 38: 123.
16. McBride JH, Kim SS, Rodgerson DO, Reyes AF, Ota MK. Measurement of cyclosporine by liquid chromatography and three immunoassays in blood from liver, cardiac, and renal transplant recipients. Clin Chem 1992: 38: 2300.
17. Armijo JA, Navarro FA, Angeles de Cos M. Is the monoclonal fluorescence polarization immunoassay for cyclosporine specific? Comparison with specific radioimmunoassay Ther Drug Monit 1992: 14: 333.
18. Morris RG. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring. Ther Drug Monit 2000: 22: 160.
19. Blick KE, Melouk SH, Fry HD, Gillum RL. A validation study of selected methods routinely used for measurement of cyclosporine. Clin Chem 1990: 36: 670.
20. Oshima K, Kanda Y, Nakasone H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008: 83: 226.